Why Do IL-1 Inhibitors Work When Colchicine Fails?
At a Glance
IL-1 inhibitors are targeted biologic medications that neutralize Interleukin-1 beta, the specific inflammatory chemical overproduced in FMF. They effectively stop flares in patients who are colchicine-resistant, offering a precision approach when standard therapy fails.
If you have been told you are “colchicine-resistant,” it is natural to wonder why a new, often expensive injectable medication will work when your daily pills have not. The answer lies in how these medications target your immune system. Colchicine works broadly by altering the function of white blood cells to calm down general inflammation [1][2]. When that broad approach is not enough to stop your flares, doctors switch to a class of biologic medications called IL-1 inhibitors (such as Kineret, Ilaris, or Arcalyst). These biologics are precision tools; rather than calming the whole immune system, they specifically hunt down and neutralize the exact inflammatory chemical—called Interleukin-1 beta (IL-1β)—that your body overproduces due to Familial Mediterranean Fever (FMF) [3][4].
How Colchicine Works: The Broad Approach
Colchicine is the cornerstone of FMF treatment and is highly effective for most patients in preventing flares and long-term complications like secondary AA amyloidosis [1][5].
It works by binding to structures inside your cells called microtubules, which act like the scaffolding or skeleton of the cell [2]. By altering these structures, colchicine makes it harder for your white blood cells—specifically neutrophils, the cells that rush to the site of inflammation—to travel and congregate [1]. By slowing down these inflammatory responder cells, colchicine essentially puts a speed limit on your immune system’s overreactions [2].
However, “colchicine resistance” happens when a patient continues to have persistent attacks or elevated inflammatory markers despite taking the highest dose they can tolerate [6][7]. In these cases, slowing down the white blood cells is not enough to stop the root cause of the flares.
The Root Cause of FMF: The Pyrin Inflammasome
To understand why biologics work, we have to look at the exact genetic error in FMF. FMF is caused by mutations in the MEFV gene, which provides instructions for making a protein called pyrin [8].
Normally, pyrin acts as a guard that detects bacterial danger. When activated, it builds a machine called an inflammasome that pumps out a powerful inflammatory chemical signal called Interleukin-1 beta (IL-1β) [9]. In FMF, the mutated pyrin protein is faulty. Its “off switch” is broken, causing the pyrin inflammasome to activate too easily and pump out massive amounts of IL-1β even when there is no infection [10][11]. This flood of IL-1β is what drives your fevers, joint pain, and abdominal attacks [12].
How Biologics Work: The Precision Approach
When colchicine’s broad effect isn’t enough, doctors introduce IL-1 inhibitors. These are laboratory-made proteins (biologics) designed to do exactly one job: shut down the effects of that specific IL-1β chemical [3]. They do not cure the underlying MEFV mutation, but they intercept the chemical fallout.
There are three main IL-1 inhibitors used for FMF, and they act like different types of security against IL-1β:
- Kineret (anakinra): This medication blocks the receptor (the “keyhole”) on your cells [13]. Even if your body makes too much IL-1β, the chemical cannot lock into your cells to trigger inflammation [14]. It is taken as a daily self-injection at home [15].
- Ilaris (canakinumab): This is an antibody that acts like a heat-seeking missile. It binds directly to the circulating IL-1β chemical itself and neutralizes it before it can reach your cells [16][17]. It is usually injected every 4 to 8 weeks [18][19].
- Arcalyst (rilonacept): This works as a trap. It circulates in your bloodstream and catches the IL-1β chemical, preventing it from interacting with your cells [20]. It is taken as a weekly self-injection [21].
Why the Switch Matters (and What to Watch For)
By shifting from colchicine to an IL-1 inhibitor, your treatment moves from broadly calming the immune cells to precisely intercepting the specific chemical causing the problem. Studies show that targeted IL-1 inhibition is highly effective at reducing the frequency of flares, normalizing inflammatory markers, and improving quality of life in patients who are resistant to or cannot tolerate colchicine [22][23]. Patients often notice a significant reduction in flare severity and frequency shortly after starting the biologic [19].
Important Safety Considerations:
Because biologics are precision medications that suppress a specific part of your immune system, they carry different risks than colchicine. By blocking IL-1β, you are lowering your body’s defense against certain infections [24]. Therefore, while on an IL-1 inhibitor:
- You may be at higher risk for serious infections, and a new fever could be a sign of an infection rather than an FMF flare [25]. You will need careful monitoring and clear instructions from your doctor on when to seek immediate medical attention [26].
- Injection site reactions (redness, swelling, or pain where the shot was given) are common, especially with daily medications like anakinra [27].
- You will likely still need colchicine: It is important to know that many patients continue to take daily colchicine alongside their new biologic injections. While the biologic controls your flares, the colchicine maintains protection against long-term kidney complications like secondary AA amyloidosis [28].
Note: The financial cost of biologics can be significant, but most drug manufacturers offer robust financial assistance or copay programs that your doctor’s office or specialty pharmacy can help you navigate.
Common questions in this guide
Why do IL-1 inhibitors work for FMF when colchicine does not?
Do I need to stop taking colchicine if I start a biologic for FMF?
What are the main IL-1 inhibitors used to treat FMF?
What are the risks of taking IL-1 inhibitors?
How will my doctor know if the biologic is working for my FMF?
Questions for Your Doctor
6 questions
- •Given my history with colchicine, which specific IL-1 inhibitor schedule (daily, weekly, or monthly) best balances my flare control and lifestyle?
- •Should I continue taking my daily colchicine alongside the new biologic injection to protect my kidneys from secondary AA amyloidosis?
- •What specific blood markers (like SAA or CRP) will we use to track if the biologic is effectively neutralizing the inflammation?
- •Since this medication suppresses part of my immune system, what specific signs of infection should prompt me to go to the ER or call your office rather than assuming it is an FMF fever?
- •What vaccines do I need to update before starting a biologic, and are there any live vaccines I should avoid while on this medication?
- •Can your office connect me with the manufacturer's copay assistance programs to help manage the cost of these injections?
Questions for You
4 questions
- •What is the highest dose of colchicine I have been able to tolerate, and what exact symptoms or side effects kept me from going higher?
- •How many distinct flares have I experienced in the last year despite taking my colchicine exactly as prescribed?
- •Am I more comfortable incorporating a daily quick injection at home, or would I prefer an injection every four to eight weeks that might require a clinic visit?
- •Do I have any lab results from my previous appointments showing elevated inflammation (like CRP or SAA) during times when I felt relatively normal?
Related questions
References
References (28)
- 1
Familial Mediterranean Fever: Assessing the Overall Clinical Impact and Formulating Treatment Plans.
Manna R, Rigante D
Mediterranean journal of hematology and infectious diseases 2019; (11(1)):e2019027 doi:10.4084/MJHID.2019.027.
PMID: 31205631 - 2
Colchicine--Update on mechanisms of action and therapeutic uses.
Leung YY, Yao Hui LL, Kraus VB
Seminars in arthritis and rheumatism 2015; (45(3)):341-50.
PMID: 26228647 - 3
Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial.
Ben-Zvi I, Kukuy O, Giat E, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2017; (69(4)):854-862 doi:10.1002/art.39995.
PMID: 27860460 - 4
Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever.
Laskari K, Boura P, Dalekos GN, et al.
The Journal of rheumatology 2017; (44(1)):102-109 doi:10.3899/jrheum.160518.
PMID: 28042127 - 5
[Familial Mediterranean fever].
Georgin-Lavialle S, Hentgen V, Stankovic Stojanovic K, et al.
La Revue de medecine interne 2018; (39(4)):240-255 doi:10.1016/j.revmed.2018.02.005.
PMID: 29526329 - 6
Colchicine resistance: Associated factors and its effect on health-related quality of life in patients with familial Mediterranean fever.
Erdem Gürsoy D, Gezer HH, Öz N, et al.
International journal of rheumatic diseases 2022; (25(11)):1239-1245 doi:10.1111/1756-185X.14407.
PMID: 35903906 - 7
French protocol for the diagnosis and management of familial Mediterranean fever.
Georgin-Lavialle S, Savey L, Cuisset L, et al.
La Revue de medecine interne 2023; (44(11)):602-616 doi:10.1016/j.revmed.2023.10.441.
PMID: 37903671 - 8
Non-amyloid liver involvement in familial Mediterranean fever: A systematic literature review.
Fraisse T, Savey L, Hentgen V, et al.
Liver international : official journal of the International Association for the Study of the Liver 2020; (40(6)):1269-1277 doi:10.1111/liv.14445.
PMID: 32196885 - 9
[Role of genetics in familial Mediterranean fever].
Kallinich T, Orak B, Wittkowski H
Zeitschrift fur Rheumatologie 2017; (76(4)):303-312 doi:10.1007/s00393-017-0265-9.
PMID: 28154935 - 10
Familial Mediterranean fever mutations are hypermorphic mutations that specifically decrease the activation threshold of the Pyrin inflammasome.
Jamilloux Y, Lefeuvre L, Magnotti F, et al.
Rheumatology (Oxford, England) 2018; (57(1)):100-111 doi:10.1093/rheumatology/kex373.
PMID: 29040788 - 11
Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation.
Van Gorp H, Saavedra PH, de Vasconcelos NM, et al.
Proceedings of the National Academy of Sciences of the United States of America 2016; (113(50)):14384-14389 doi:10.1073/pnas.1613156113.
PMID: 27911804 - 12
An Update on Familial Mediterranean Fever.
Lancieri M, Bustaffa M, Palmeri S, et al.
International journal of molecular sciences 2023; (24(11)) doi:10.3390/ijms24119584.
PMID: 37298536 - 13
The clinical role of anakinra in the armamentarium against familial Mediterranean fever.
Parlar K, Ates MB, Egeli BH, Ugurlu S
Expert review of clinical immunology 2024; (20(5)):441-453 doi:10.1080/1744666X.2023.2299230.
PMID: 38133629 - 14
Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).
El Hasbani G, Jawad A, Uthman I
Orphanet journal of rare diseases 2019; (14(1)):224 doi:10.1186/s13023-019-1201-7.
PMID: 31615541 - 15
PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis.
Powers NE, Swartzwelter B, Marchetti C, et al.
The Journal of biological chemistry 2020; (295(3)):868-882 doi:10.1074/jbc.RA119.010340.
PMID: 31819009 - 16
Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
De Benedetti F, Gattorno M, Anton J, et al.
The New England journal of medicine 2018; (378(20)):1908-1919 doi:10.1056/NEJMoa1706314.
PMID: 29768139 - 17
Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series.
Sendogan DO, Saritas H, Kumru G, et al.
Transplantation proceedings 2019; (51(7)):2292-2294 doi:10.1016/j.transproceed.2019.03.049.
PMID: 31400972 - 18
Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study.
Babaoglu H, Varan O, Kucuk H, et al.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2020; (26(1)):7-13 doi:10.1097/RHU.0000000000000873.
PMID: 30048391 - 19
Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry.
Sag E, Akal F, Atalay E, et al.
Rheumatology (Oxford, England) 2020; (59(11)):3324-3329 doi:10.1093/rheumatology/keaa121.
PMID: 32306038 - 20
Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists' lens.
Cattalini M, Soliani M, Lopalco G, et al.
Internal and emergency medicine 2016; (11(6)):781-91 doi:10.1007/s11739-016-1466-y.
PMID: 27221072 - 21
Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis.
Schwier NC
The Annals of pharmacotherapy 2022; (56(5)):572-581 doi:10.1177/10600280211036499.
PMID: 34459270 - 22
A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever.
Kuemmerle-Deschner JB, Gautam R, George AT, et al.
Rheumatology (Oxford, England) 2020; (59(10)):2711-2724 doi:10.1093/rheumatology/keaa205.
PMID: 32533192 - 23
Canakinumab for the treatment of familial Mediterranean fever.
Ozdogan H, Ugurlu S
Expert review of clinical immunology 2017; (13(5)):393-404 doi:10.1080/1744666X.2017.1313116.
PMID: 28362189 - 24
Interleukin (IL)-1β and IL-10 Host Responses in Patients With Staphylococcus aureus Bacteremia Determined by Antimicrobial Therapy.
Volk CF, Burgdorf S, Edwardson G, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020; (70(12)):2634-2640 doi:10.1093/cid/ciz686.
PMID: 31365924 - 25
Interleukin-1 Inhibitors for Management of Recurrent Pericarditis After Thoracic Organ Transplantation.
Rajput B, Singh A, Garshick MS
JACC. Case reports 2026; (31(6)):106322 doi:10.1016/j.jaccas.2025.106322.
PMID: 41342818 - 26
Anti-interleukin 1 agents for the treatment of recurrent pericarditis: a systematic review and meta-analysis.
Imazio M, Andreis A, Piroli F, et al.
Heart (British Cardiac Society) 2021; (107(15)):1240-1245 doi:10.1136/heartjnl-2020-318869.
PMID: 33737453 - 27
Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system.
Liu H, Yan W, Li J, et al.
Frontiers in pharmacology 2025; (16()):1483669 doi:10.3389/fphar.2025.1483669.
PMID: 40371323 - 28
Familial Mediterranean fever in childhood: a single-center experience.
Barut K, Sahin S, Adrovic A, et al.
Rheumatology international 2018; (38(1)):67-74 doi:10.1007/s00296-017-3796-0.
PMID: 28828621
This page explains treatments for Familial Mediterranean Fever for educational purposes only. Always consult your rheumatologist or healthcare provider before making any changes to your medication regimen.
Get notified when new evidence is published on Familial Mediterranean fever.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.